Biotech Updates: Acrivon CLIA Lab, Lilly M&A Spree, Defence Radiopharma COO
Acrivon launched a CLIA-certified lab. Eli Lilly disclosed over 5 trillion won in M&A and licensing. Defence Therapeutics named a new radiopharmaceutical COO.
Eli Lilly and Company
CompanyAlso known as: Eli Lilly, Eli Lilly and Co., Lilly, Lilly Oncology
Company Profile
Eli Lilly and Company is an American multinational pharmaceutical company headquartered in Indianapolis, Indiana. Founded in 1876, it sells products in about 125 countries and is publicly traded on the NYSE as LLY. Its major products include tirzepatide (Mounjaro and Zepbound) and other therapies in diabetes, oncology, and immunology.
- Website
- https://www.lilly.com
- Headquarters
- Indianapolis, Indiana, US
- Founded
- 1876
- Stock Ticker
- NYSE:LLY
Related News
CRISPR Technology Advances: Off-Target Benchmark, New Data, and Licensing Deal
IDT's study showed UNCOVERseq achieved 97.6% sensitivity and 78% precision for CRISPR off-target nomination. Scribe will present new data at ASGCT and EAS, including STX-1150. Watchmaker licensed CRISPR-Cas9 IP for NGS normalization.
Pharma Earnings Roundup: Alnylam, Neurocrine, AbbVie, Merck, Roche Miss Expectations
Several drugmakers saw shares fall after earnings missed expectations. Alnylam's Amvuttra sales disappointed despite growth; Neurocrine's guidance underwhelmed; AbbVie's Imbruvica and Roche's Vabysmo fell short of consensus.
UK Regulator Reports 150,000 Adverse Events and 153 Deaths Linked to Weight-Loss Jabs
UK data links 150+ deaths to weight-loss jabs. A new study finds a vegan diet led to 5.9kg average loss in 4 months vs 6.9kg over 9 months for semaglutide.
Orforglipron Beats Oral Semaglutide in Type 2 Diabetes Trial; Hair Loss on GLP-1s Addressed
Orforglipron beat oral semaglutide on blood sugar and weight in type 2 diabetes, with higher discontinuation rates. GLP-1 hair loss is typically temporary telogen effluvium.
AI in Drug Discovery: Milestones, Limitations and the Push for Clinically Relevant Data
AI is transforming drug discovery across target ID, molecule design and trial optimization. Milestones include regulatory qualification of digital-twin controls and positive Phase 2a data, though 90-95% of candidates still fail.
FDA Finalizes Psychedelic Clinical Trial Guidance; States Move on Ibogaine Research
FDA final guidance sets standards for psychedelic clinical trials. Federal agencies and states are advancing psilocybin and ibogaine research, and Eli Lilly is acquiring AtaiBeckley for $2.8 billion.
Revolution Medicines Stock Surges 132% on Daraxonrasib Trial Data
Revolution Medicines (RVMD) shares up 132% YTD. Daraxonrasib beat chemo in pancreatic cancer (13.2 vs 6.7 months median OS). Company has no marketed products and a $39B valuation.
GLP-1 Boom: One in Eight U.S. Adults Now Taking Drugs, Driving Manufacturing and Consumer Shifts
One in eight U.S. adults now takes a GLP-1, and prescriptions among non-diabetics rose 700% since 2019. The market is projected to reach $200 billion by 2030, driving manufacturing investments and consumer food shifts.
Lawmakers Probe Drugmakers Over China Clinical Trials as U.S. Seeks to Counter Biotech Rise
Lawmakers opened national security probes into Merck, AbbVie and others over China drug trials. A survey finds China closing in on U.S. biotech leadership, and HHS launched clinical trial reforms to counter the rise.
Related Clinical Trials
| NCT ID | Title | Status | Phase |
|---|---|---|---|
| NCT07775300 |
A Study of Brenipatide (LY3537031) in Adult Participants With Major Depressive Disorder |
NOT_YET_RECRUITING | PHASE3 |
| NCT07767487 |
A Study of LY4226695 in Healthy Participants |
NOT_YET_RECRUITING | PHASE1 |
| NCT07765511 |
A Study of Macupatide (LY3532226) in Participants With Obesity or Overweight Without Type 2 Diabetes |
NOT_YET_RECRUITING | PHASE1 |
| NCT07765498 |
A Study of LY4355756 in Healthy Participants |
NOT_YET_RECRUITING | PHASE1 |
| NCT07759245 |
A Study of Brenipatide (LY3537031) in Adult Participants With Moderate-to-Severe Chronic Obstructive Pulmonary Disease (COPD) |
NOT_YET_RECRUITING | PHASE2 |
| NCT07756359 |
Tirzepatide for Ileal Pouch-anal Anastomosis (IPAA) and Chronic High Bowel Frequency (I8F-NS-X008) |
NOT_YET_RECRUITING | PHASE4 |
| NCT07738614 |
A Study of Eloralintide (LY3841136) in Participants With Obesity or Overweight |
RECRUITING | PHASE1 |
| NCT07734870 |
Tirzepatide for Treatment of CCCA |
NOT_YET_RECRUITING | PHASE2 |
| NCT07707375 |
A Study of LY4268989 (MORF 057) in Healthy Participants |
RECRUITING | PHASE1 |
| NCT07701083 |
A Study of Eloralintide (LY3841136) in Healthy Participants |
RECRUITING | PHASE1 |